BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia - Wikidata - awgldk - TriplyDB

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

http://www.wikidata.org/entity/Q36478440

about

Oxidative stress responses and NRF2 in human leukaemia Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.Molecular biology of bcr-abl1-positive chronic myeloid leukemia.A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases.Src family kinases and their role in hematological malignancies.Natural course and biology of CML.FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.Targeting Fyn in Ras-transformed cells induces F-actin to promote adherens junction-mediated cell-cell adhesion.Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia.Oxidative stress promotes transcriptional up-regulation of Fyn in BCR-ABL1-expressing cells.Potent and selective inhibition of SH3 domains with dirhodium metalloinhibitors.Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the activated AMPK/mTOR signaling pathway.Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.FYNagling divergent adhesive functions for Fyn in keratinocytes.Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

P2860

Q26864239-97DD10EF-F1A9-4F30-AA8E-2D3FADB43CCB Q28235184-AC6A19AE-DDF3-4125-A1CC-617D6F9D55C8 Q33643375-28B0CB77-7FBA-49C8-9D5A-5736BB8581BF Q34532048-46AB0065-B170-46AF-B454-352CC873F193 Q36240238-F70828D1-5CAF-4E10-9AAB-7044672925E6 Q36414254-A747D681-6403-466B-9CF8-BD08E71BD53C Q36646486-7783DE50-F281-48E0-ADFC-A2623E2C8C89 Q37283128-A14CDB22-B9FC-4268-880D-FC66F8FB0E5A Q37662204-71B67CC1-D8CF-4F01-B225-BCE1C03D0101 Q37733781-04FE38F0-FD7F-4EF2-992F-D30DAFF3BDCD Q38217719-34E78173-8266-4F91-AE05-BD8181AF4263 Q38392667-D311CACC-F6D9-452B-A04A-A40D22AC7E92 Q38796275-C6CE906B-3422-45C1-B210-2A805198B951 Q38979793-7F3F4844-5734-48CF-B61C-5A1BC7D3C093 Q39392511-71B5840B-9007-47B4-BD7D-0DAD7F6E0153 Q39433276-F0DECEF8-6A0E-4264-954C-14E91311D8F6 Q42186300-D98D2AF2-ECE7-4F5C-B7EC-D5D456656874 Q45073074-9254648B-B1FE-4B48-9F99-9ADBC9E0EC1E Q50053633-7802B9F9-B186-43F8-9845-3E926AFAAFBC Q53197147-87C2F716-51AE-4C61-B935-FF57DD3A79B6 Q54341168-F83F0347-F625-4C7F-875A-2BA5CE2E2EB4 Q54978822-24F9E938-BC3B-4F6E-AE12-F79F7D00E889

P2860

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

http://www.wikidata.org/entity/Q36478440

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

@ast

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

@en

type

label

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

@ast

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

@en

prefLabel

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

@ast

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

@en

P1433

Q36478440-5DF0B055-27E7-49B9-92BD-A7B0AC77C6F5

P1476

Q36478440-0D0945FA-FC5D-4EAD-A2C4-B1D4F82872BF

P2093

Q36478440-0A99DBFA-3A22-4C3A-8D8A-642A6BEC8929

Q36478440-13B63591-0707-4608-8F3A-01FC662DBCB8

Q36478440-42CAF852-71B2-42EA-854B-8092DFEFFDC8

Q36478440-48756F90-B408-4811-8740-8535B9B5D752

Q36478440-568E67DA-2231-4CFE-9630-A9BDF6194D9D

Q36478440-7A768B52-17D7-40C7-926A-C0B6CD9C8822

Q36478440-7D66D752-7840-43AC-8912-C2CD9ED20B6E

Q36478440-C0CE28F0-4556-4EF7-B196-3B600D7B8B1B

Q36478440-CCF72608-7B53-4977-A84A-DD7C3AF2F626

Q36478440-E1E74ABE-EB68-494E-A4DB-D53AAEB1B36D

P2860

Q36478440-2D9CA8E4-E7D2-429A-9DDE-532CF5942013

Q36478440-4066C3C8-2D52-4A11-8C7C-B7115F276ACC

Q36478440-63474D07-D4A9-4082-8466-09DDED2318B5

Q36478440-765377C4-4E73-49A4-9A48-C312E40ABD61

Q36478440-7ED44DFA-73D8-449D-9402-38C57DCE1FD8

Q36478440-8CFC861D-6714-47B6-B454-80C89CF5900A

Q36478440-8E49E953-BD74-4987-A162-AFEBD2317FA8

Q36478440-B111FE2A-7936-4F87-A758-0FF6E8710865

Q36478440-C91813B3-97C3-4BA7-B6F1-6DCDAAF1F31F

Q36478440-CA8D9928-05F3-4C61-9547-37A0419F0449

P304

Q36478440-2F81DA68-E0AA-45A4-BB7C-B8D9124F6726

P31

Q36478440-9CD627D7-8C54-42F4-8640-95D75CB313FA

P356

Q36478440-C1A2E2D5-8A17-4F5A-8000-E38A899187C4

P407

Q36478440-B84F5E11-7096-480D-BE07-DB5E2F0FBD42

P433

Q36478440-ABF6A5C7-517C-417B-A2CF-E4F0200434B7

P478

Q36478440-2FA3E01E-2442-47C7-8DF0-F599BA483865

P577

Q36478440-D6A58CAC-5768-4D40-BBC6-12936E4472AF

P5875

Q36478440-ABD9B563-3B25-4EEC-BA46-223F5FACD238

P698

Q36478440-E304EFFF-E8AD-44E4-B184-9CE6E40750BF

P921

Q36478440-9DF064E6-27EE-4185-9F1E-1FBBFE616F6D

P932

Q36478440-ADD8631C-76B3-4015-8E62-2C6183D8F14F

P356

BLOOD-2007-05-091769

P1433

P1476

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

@en

P2093

Adrienne Howard

http://www.w3.org/2001/XMLSchema#string

Claudia Miller

http://www.w3.org/2001/XMLSchema#string

Hesham M Amin

http://www.w3.org/2001/XMLSchema#string

Joya Chandra

http://www.w3.org/2001/XMLSchema#string

Kechen Ban

http://www.w3.org/2001/XMLSchema#string

Mark Munsell

http://www.w3.org/2001/XMLSchema#string

Menashe Bar-Eli

http://www.w3.org/2001/XMLSchema#string

Quan Lin

http://www.w3.org/2001/XMLSchema#string

Ralph B Arlinghaus

http://www.w3.org/2001/XMLSchema#string

Xiaohong Leng

http://www.w3.org/2001/XMLSchema#string

P2860

Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.

Gene expression changes associated with progression and response in chronic myeloid leukemia.

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.

Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.

Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

P304

2904-2908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-05-091769

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5670733

http://www.w3.org/2001/XMLSchema#string

P698

18180382

http://www.w3.org/2001/XMLSchema#string

P921

P932

2254539

http://www.w3.org/2001/XMLSchema#string